The
slide to be stained for Mismatch repair protein MSH2
(MSH2) comprised:
1. Tonsil, 2. Colon adenocarcinoma with normal expression of MSH2 protein,
3-4. Colon adenocarcinoma with loss of MSH2 protein.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a MSH2 staining as optimal
included:
- A strong and distinct nuclear staining of
virtually all the cells in the tonsil and the colon
adenocarcinoma no. 2 – including epithelial cells, stromal cells,
lymphocytes, muscle cells etc.
- A negative reaction in the neoplastic
cells of the colon adenocarcinomas no. 3 & 4, while a distinct
nuclear reaction should be seen in all other cells. A weak cytoplasmic reaction was accepted.
51 laboratories participated in the
assessment. At the assessment 10 achieved optimal (20 %), 27 good
(53 %), 7 borderline (14 %) and 7 (14 %) poor marks.
The following 5 antibody clones were used:
mAb clone G219-1129 (BD Pharmingen, n=10; Ventana, n=7; Cell
Margue, n=2; BioGenex, n=1)
mAb clone FE11 (Calbiochem/Oncogene, n=7; Biocare, n=7;
Zytomed, n=1)
mAb clone 25D12 (Novocastra, n=8)
mAb clone 27 (BD Pharmingen/Transduction, n=7)
mAb clone GB12 (Calbiochem, n=1)
Optimal staining for MSH2 in this assessment
was obtained with the mAbs clones 25D12, G219-1129,
27 and FE11 as follows:
25D12: 3 out of 8 laboratories (38%)
produced an optimal stain. Sufficient stains (optimal or good) were
seen in 7 cases (88%). The optimal protocols were all based on heat
induced epitope retrieval (HIER) using Tris-EDTA/EGTA pH 9 and the
Ab was diluted in the range of 1:10 - 1:60 depending on the total
sensitivity of the protocol employed.
G219-1129: 3 out of 20 laboratories
(15%) produced an optimal stain. Sufficient stains were seen in 14
cases (70%). The optimal protocols were all based on HIER using
either Tris-EDTA/EGTA pH 9, EDTA/EGTA pH 8 or Cell Conditioning 1
(CC1, Ventana). The Ab could both be applied as a Ready To Use (RTU)
product from Ventana (used
by 2 out of 3) and as a concentrate diluted
1:200.
27: 2 out of 7 laboratories (29%)
produced an optimal stain. Sufficient stains were seen in 6 cases
(86%). The optimal protocols were both based on HIER using
Tris-EDTA/EGTA pH 9. The Ab was diluted in the range of 1:800 -
1:1000.
FE11: 2 out of 15 laboratories (13%)
produced an optimal stain. Sufficient stains were seen in 10 cases
(67%). The optimal protocols were based on HIER using Tris-EDTA/EGTA
pH 9. The Ab was used in in the range of 1:25 to 1:400 depending on
the total sensitivity of the protocol employed.
The most frequent causes of insufficient
staining were:
- Too diluted primary antibody
- Insufficient HIER.
The prevalent feature of an insufficient
staining was a too weak or false negative staining of the majority
of the cells that were expected to stain (Fig. 2a - Fig. 2d). As the
identification of an MSH2 loss is characterized by a negative
immunoreaction of the neoplastic cells, it is of decisive importance
that the benign cells can be demonstrated, thus serving as
internal positive control. Stromal cells of the tumours and normal enterocytes should be strongly positive. Lymphatic tissue as in the
appendix or tonsil are appropriate as positive control. The
optimal protocols were all able to give a strong staining, not only
in the most active and proliferating cells in the germinal centres
but also in the
dormant lymphocytes in the mantle zone (Figs. 3a-b).
In concordance with the previous assessment of
MSH2, run 13 2005, the mAb clones FE11, 27 and 25D12 could all be
used to obtain an optimal staining. However, it was observed that the
latter and the mAb clone G219-1129 also gave a weak to moderate cytoplasmic reaction and labelled a reduced proportion of
cells expected to stain for MSH2. The overall pass rate and proportion of sufficient
stains was 73% (compared to 43% in previous run). Many
factors may contribute to the improvement and it can be difficult to
find specific explanations for the improvement as many
laboratories have changed their entire system and the number of
participants almost doubled.
Conclusion
The mAbs clones 25D12, G219-1129, 27* and
FE11 are all useful for the demonstration of MSH2. All clones
require efficient HIER (preferable in an alkaline buffer. The
concentration of the primary Ab and the immunohistochemical protocol
should be carefully calibrated, so all the lymphocytes in the tonsil
show a distinct nuclear reaction.
* withdrawn from the market 2007. |